STOCK TITAN
  1. Home
  2. Sec-filings
  3. AXGN
  4. [Form 4] Axogen, Inc. Insider Trading Activity

Axogen (AXGN) director Alan Levine granted 4,392 RSUs valued at $185K

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Levine Alan M reported acquisition or exercise transactions in this Form 4 filing.

Axogen, Inc. director Alan M. Levine received an annual equity award in the form of 4,392 restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of Axogen common stock. The grant is valued at $185,000 as of the grant date.

The RSUs were awarded for service on the Board of Directors and vest on June 24, 2027, the one-year anniversary of the grant date. Following this grant, Levine directly holds 4,392 RSUs linked to Axogen common stock.

Positive

  • None.

Negative

  • None.
Insider Levine Alan M
Role null
Type Security Shares Price Value
Grant/Award Restricted Stock Units 4,392 $0.00 --
Holdings After Transaction: Restricted Stock Units — 4,392 shares (Direct, null)
Footnotes (1)
  1. Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock. Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $185,000 valuation as of the grant date and vests on June 24, 2027, the one-year anniversary of the grant date.
RSUs granted 4,392 units Annual equity grant for Board service
Grant valuation $185,000 Valuation as of grant date for equity award
RSUs after transaction 4,392 units Total restricted stock units held directly after grant
Vesting date June 24, 2027 One-year anniversary of the grant date
RSU-to-share ratio 1 RSU : 1 share Each RSU represents one Axogen common share
Restricted Stock Units financial
"Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock."
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
equity grant financial
"Annual equity grant for service as Director on the Axogen, Inc. Board of Directors."
Board of Directors financial
"Annual equity grant for service as Director on the Axogen, Inc. Board of Directors."
The Board of Directors is a group of people chosen by a company's owners to help make big decisions and oversee how the company is run. They act like a team of advisors or managers, making sure the company stays on track and meets its goals. Their choices can influence the company's success and how it grows.
grant date financial
"The number of shares pursuant to the equity grant is based on a $185,000 valuation as of the grant date"
The grant date is the day a company formally gives an employee or contractor the right to receive stock-based compensation, such as stock options or restricted shares. It matters to investors because it fixes key terms—like the price, the start of the ownership clock, and when the award will affect the company’s financial statements and share count—so it can influence dilution, reported expenses, and potential future selling pressure.
vests financial
"and vests on June 24, 2027, the one-year anniversary of the grant date."
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Levine Alan M
(Last)(First)(Middle)
C/O AXOGEN, INC. 13631 PROGRESS BLVD.
SUITE 400
(Street)
ALACHUA FLORIDA 32615
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
Axogen, Inc. [ AXGN ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/24/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Restricted Stock Units(1)06/24/2026A4,392 (2) (2)Common Stock4,392$04,392D
Explanation of Responses:
1. Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock.
2. Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $185,000 valuation as of the grant date and vests on June 24, 2027, the one-year anniversary of the grant date.
Remarks:
/s/ Marc Began, as attorney-in-fact for Alan Levine06/26/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did Axogen (AXGN) director Alan M. Levine report in this Form 4?

Alan M. Levine reported receiving 4,392 restricted stock units as an equity grant. The award compensates his service on Axogen’s Board of Directors and vests after one year, converting into an equal number of Axogen common shares upon settlement.

How many Axogen (AXGN) restricted stock units did Alan M. Levine receive?

He received 4,392 restricted stock units tied to Axogen common stock. Each unit represents a contingent right to receive one share, giving him potential ownership of 4,392 shares once vesting conditions are satisfied and the units are settled into stock.

What is the reported dollar value of Alan M. Levine’s Axogen (AXGN) RSU grant?

The equity grant is based on a valuation of $185,000 as of the grant date. This valuation determined the number of restricted stock units awarded, resulting in 4,392 RSUs being granted as compensation for his Board service.

When do Alan M. Levine’s Axogen (AXGN) restricted stock units vest?

The restricted stock units vest on June 24, 2027, one year after the grant date. Vesting means the units become earned, after which each RSU is eligible to settle into one share of Axogen common stock, subject to plan terms.

What does each restricted stock unit represent in this Axogen (AXGN) filing?

Each restricted stock unit represents a contingent right to receive one share of Axogen common stock. The units have no purchase price and convert into shares only if vesting conditions are met, aligning director compensation with shareholder interests over time.

Is Alan M. Levine’s Form 4 transaction a market buy or sell of Axogen (AXGN) shares?

No, this Form 4 reflects a grant of restricted stock units, not an open-market trade. The RSUs are a compensation award with a reported grant-date valuation of $185,000, vesting after one year rather than being bought or sold in the market.